|
Jul 29
|
Hansa Biopharma announces key executive appointments to support continued growth
|
|
Jul 17
|
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
|
|
Jun 11
|
Hansa Biopharma to attend BIO International Convention
|
|
Mar 11
|
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
|
|
Oct 7
|
Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
|
|
Feb 2
|
Hansa Biopharma Year-end report January-December 2023
|
|
Dec 7
|
Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)
|
|
Dec 5
|
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
|
|
Jul 20
|
Hansa Biopharma half year report 2023
|
|
Jul 19
|
First patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitis
|